Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
EM

OTC · EMMA

Emmaus Life Sciences, Inc.

Healthcare · Biotechnology

$0.03

Down-$0.01 (-31.50%)

Updated Nov 5, 2026, 7:56 AM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
702.52K
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.01 – $0.09
Volume
10K
Avg. volume
69.57K

Price performance · EMMA

EMMA price history

1M range · 13 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

EMMA closed at $0.04 after 13 trading sessions, down 33.67% for the selected period.

Last close
$0.04
Period change
-33.67%
Period low
$0.04
Period high
$0.06
Daily close
View OHLC price history
EMMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.04$0.04$0.04$0.0410K
Oct 29, 2026$0.0313$0.0352$0.03$0.035238.04K
Oct 28, 2026$0.0356$0.0407$0.0356$0.04077.2K
Oct 27, 2026$0.0461$0.0461$0.04$0.0441.72K
Oct 26, 2026$0.0461$0.0461$0.046$0.04615.5K
Oct 22, 2026$0.0576$0.0576$0.0576$0.0576301
Oct 20, 2026$0.046$0.065$0.046$0.06420.39K
Oct 19, 2026$0.0425$0.0563$0.042$0.0519.64K
Oct 16, 2026$0.0421$0.0649$0.0421$0.058437.24K
Oct 14, 2026$0.0584$0.0584$0.0584$0.0584350
Oct 13, 2026$0.05$0.06$0.05$0.0647K
Oct 9, 2026$0.0495$0.0495$0.0428$0.042826.06K
Oct 8, 2026$0.0628$0.0628$0.0603$0.060310.8K

Latest EMMA news

The latest Smart Investors Daily articles mentioning EMMA.

Stock researchCompany · Overview

EMMA research

Overview

Company profile and research snapshot.

Company profile

EMMAUS LIFE SCIENCES INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer

TORRANCE, Calif., August 31, 2026--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC).

Benzinga · Nov 14, 2025

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences reported a 38% decline in net revenues for Q3 2025, attributed to generic L-Glutamine competition and lower sales in the Middle East North Africa region. The company experienced a net loss of $2.1 million and reduced operating expenses by 43%.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By